FAP and adenocarcinoma: [18F]AlF-FAP-2286 demonstrated superior imaging contrast with high target uptake and satisfactory retention in both mouse models and in cancer patients.100 Baum et al. reported the first-in-human results of [177Lu]Lu-FAP-2286 in 11 patients with advanced adenocarcinomas of the pancreas, breast, rectum, or ovary.